cenegermin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5235 1772578-74-1

Description:

MoleculeDescription

Synonyms:

  • cenegermin
  • oxervate
Cenegermin is a recombinant form of human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors. Nerve growth factor receptors are expressed in the anterior segment of the eye (cornea, conjunctiva, iris, ciliary body, and lens), by the lacrimal gland, and by posterior segment intraocular tissues. The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity.
  • Molecular weight: 13261.10
  • Formula: C583H902N166O173S8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 5485.74
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 6, 2017 EMA Dompe farmaceutici s.p.a.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye pain 482.65 165.31 94 317 28355 50576358

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye pain 187.93 98.31 35 136 11560 29562796

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye pain 372.32 121.56 72 272 31553 64466835

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01XA24 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
FDA CS M0328210 Nerve Growth Factor
FDA EPC N0000193854 Recombinant Human Nerve Growth Factor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Neurotrophic keratitis indication 128080005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
High affinity nerve growth factor receptor Kinase AGONIST UNKNOWN DRUG LABEL
Tumor necrosis factor receptor superfamily member 16 Membrane receptor AGONIST UNKNOWN DRUG LABEL

External reference:

IDSource
B6E7K36KT8 UNII
C4541383 UMLSCUI
CHEMBL4297852 ChEMBL_ID
DB13926 DRUGBANK_ID
D11028 KEGG_DRUG
2104332 RXNORM
267667 MMSL
773954004 SNOMEDCT_US
773957006 SNOMEDCT_US
4038032 VANDF
C000647429 MESH_SUPPLEMENTAL_RECORD_UI
10381 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OXERVATE HUMAN PRESCRIPTION DRUG LABEL 1 71981-020 SOLUTION/ DROPS 20 ug OPHTHALMIC BLA 25 sections